2018CCCP&SCC:李妍教授畅谈OCT对复杂高危患者的指导价值

2018-04-08 国际循环编辑部 国际循环

复杂高危且有介入治疗指征的患者(CHIP)的经皮冠状动脉介入(PCI)治疗一直是介入治疗领域关注的焦点和难点。光学相干断层扫描(OCT)等影像学技术为上述患者的治疗提供了重要指导价值。

编者按:复杂高危且有介入治疗指征的患者(CHIP)的经皮冠状动脉介入(PCI)治疗一直是介入治疗领域关注的焦点和难点。光学相干断层扫描(OCT)等影像学技术为上述患者的治疗提供了重要指导价值。在2018中国医师协会心血管内科医师年会和2018中国南方国际心血管病学术会议“OCT指导优化CHIP策略与治疗”专场,来自空军军医大学西京医院的李妍教授结合形象的实践病例就OCT对复杂高危患者的指导价值作了专题讲座,让参会者对于如何借助OCT优化CHIP介入治疗有了更深、更形象的认识。

临床实践中,很多CHIP患者未接受治疗,更别说得到精确诊断和优化治疗了。一般来说,患者的病变越复杂,治疗时就越需借助影像学技术的指导。在众多影像学技术中,OCT有助于我们了解病变特征及管腔大小,可指导指引导丝定位等优势(图1),可优化上述患者的PCI结局,故被指南推荐用于指导CHIP患者的PCI治疗。ILUMIEN I~III系列研究等研究为应用OCT指导介入治疗提供了坚实的循证医学证据,也为临床实践中介入医生基于OCT评估结果优化CHIP介入治疗提供了重要信息。其结果显示,CHIP患者可从OCT指导的PCI治疗中获益。



图1.OCT评估的优势

总之,OCT可实现体内病理诊断,对于CHIP诊断及治疗具有重要意义。例如,OCT有助于帮助我们发现罪犯病变及造影未发现的夹层以便及时干预;可指导支架锚定区定位及支架尺寸的精确选择;对于缺血性心肌病患者的LAD临界病变PCI有指导价值,可简化和优化左主干三叉病变PCI;还可对CTO病变的随访提供重要指导性信息。更加可喜的是,具有更多优势的3D-OCT及angio-OCT融合技术有望显著改变和优化CHIP的治疗,引领CHIP介入治疗领域技术变革。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1987659, encodeId=1c6a198e659ca, content=<a href='/topic/show?id=67dd1596982' target=_blank style='color:#2F92EE;'>#SCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15969, encryptionId=67dd1596982, topicName=SCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Oct 20 22:43:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955764, encodeId=15a31955e649b, content=<a href='/topic/show?id=5b0b1022667b' target=_blank style='color:#2F92EE;'>#高危患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102266, encryptionId=5b0b1022667b, topicName=高危患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Fri Oct 26 14:43:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858324, encodeId=bcf5185832416, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Fri Jun 01 03:43:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304374, encodeId=2e923043e425, content=好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Tue Apr 10 06:55:47 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303947, encodeId=8b3930394ea3, content=不错很喜欢很实用.值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Apr 08 18:00:57 CST 2018, time=2018-04-08, status=1, ipAttribution=)]
    2018-10-20 柳叶一刀
  2. [GetPortalCommentsPageByObjectIdResponse(id=1987659, encodeId=1c6a198e659ca, content=<a href='/topic/show?id=67dd1596982' target=_blank style='color:#2F92EE;'>#SCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15969, encryptionId=67dd1596982, topicName=SCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Oct 20 22:43:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955764, encodeId=15a31955e649b, content=<a href='/topic/show?id=5b0b1022667b' target=_blank style='color:#2F92EE;'>#高危患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102266, encryptionId=5b0b1022667b, topicName=高危患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Fri Oct 26 14:43:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858324, encodeId=bcf5185832416, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Fri Jun 01 03:43:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304374, encodeId=2e923043e425, content=好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Tue Apr 10 06:55:47 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303947, encodeId=8b3930394ea3, content=不错很喜欢很实用.值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Apr 08 18:00:57 CST 2018, time=2018-04-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1987659, encodeId=1c6a198e659ca, content=<a href='/topic/show?id=67dd1596982' target=_blank style='color:#2F92EE;'>#SCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15969, encryptionId=67dd1596982, topicName=SCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Oct 20 22:43:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955764, encodeId=15a31955e649b, content=<a href='/topic/show?id=5b0b1022667b' target=_blank style='color:#2F92EE;'>#高危患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102266, encryptionId=5b0b1022667b, topicName=高危患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Fri Oct 26 14:43:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858324, encodeId=bcf5185832416, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Fri Jun 01 03:43:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304374, encodeId=2e923043e425, content=好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Tue Apr 10 06:55:47 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303947, encodeId=8b3930394ea3, content=不错很喜欢很实用.值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Apr 08 18:00:57 CST 2018, time=2018-04-08, status=1, ipAttribution=)]
    2018-06-01 habb
  4. [GetPortalCommentsPageByObjectIdResponse(id=1987659, encodeId=1c6a198e659ca, content=<a href='/topic/show?id=67dd1596982' target=_blank style='color:#2F92EE;'>#SCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15969, encryptionId=67dd1596982, topicName=SCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Oct 20 22:43:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955764, encodeId=15a31955e649b, content=<a href='/topic/show?id=5b0b1022667b' target=_blank style='color:#2F92EE;'>#高危患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102266, encryptionId=5b0b1022667b, topicName=高危患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Fri Oct 26 14:43:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858324, encodeId=bcf5185832416, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Fri Jun 01 03:43:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304374, encodeId=2e923043e425, content=好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Tue Apr 10 06:55:47 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303947, encodeId=8b3930394ea3, content=不错很喜欢很实用.值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Apr 08 18:00:57 CST 2018, time=2018-04-08, status=1, ipAttribution=)]
    2018-04-10 张新亮1853311252142e2fm

    好文章学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1987659, encodeId=1c6a198e659ca, content=<a href='/topic/show?id=67dd1596982' target=_blank style='color:#2F92EE;'>#SCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15969, encryptionId=67dd1596982, topicName=SCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Oct 20 22:43:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955764, encodeId=15a31955e649b, content=<a href='/topic/show?id=5b0b1022667b' target=_blank style='color:#2F92EE;'>#高危患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102266, encryptionId=5b0b1022667b, topicName=高危患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Fri Oct 26 14:43:00 CST 2018, time=2018-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858324, encodeId=bcf5185832416, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Fri Jun 01 03:43:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=304374, encodeId=2e923043e425, content=好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Tue Apr 10 06:55:47 CST 2018, time=2018-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303947, encodeId=8b3930394ea3, content=不错很喜欢很实用.值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Apr 08 18:00:57 CST 2018, time=2018-04-08, status=1, ipAttribution=)]
    2018-04-08 虈亣靌

    不错很喜欢很实用.值得推荐

    0

相关资讯

GW-ICC2017︱张金盈:冠状动脉分叉病变双支架策略与技术优化

经皮冠状动脉介入(PCI)治疗中冠状动脉分叉病变比例及并发症发生均较高,是最有挑战的冠状动脉病变之一,也是冠状动脉介入治疗领域的一个重点和难点。今年GW-ICC 2017大会上,来自郑州大学第一附属医院的张金盈教授就冠状动脉分叉病变的双支架策略作了专题解析。

HEART:慢性完全闭塞经皮冠状动脉介入治疗的预测因素!

近期,一项发表在杂志HEART上的研究旨在确定经皮冠状动脉介入治疗(PCI)技术对慢性完全闭塞(CTO)治疗正面和负面预测因素。此项研究对2000年至2016年期间发表的研究进行了系统评价和荟萃分析,分析了CTO PCI在人口和血管造影特征方面的成功率。使用随机效应模型计算每个预测因子的粗略OR值和95%CI。在28个人口统计学和31个血管造影变量中评估了技术和临床成功的预测因素。临床成功被定义为

许轶洲:房颤患者冠脉支架术后的抗栓治疗

  摘要:当房颤的患者合并冠心病需要接受经皮冠状动脉介入治疗(PCI)时,其术后双联抗血小板治疗和长期抗凝治疗策略的安全性一直存在质疑和争议。本文就心房颤动患者冠脉支架术后的抗血栓治疗进行综述。   心房颤动是最常见的心律失常之一,国外对心房颤动的流行病学调查表明,一般人群心房颤动的总患病率约为0.4%-1.0%,且有随年龄增长上升的趋势。房颤动(房颤)和冠心病有着很多共同的危险因素,冠

盘点:心血管疾病介入治疗指南与共识(上)

一、2016 经皮冠状动脉介入治疗术后运动康复专家共识经皮冠状动脉介入治疗( percutaneous coronaryintervention,PCI) 已成为冠心病患者最重要的血运重建手段。 然而,仅通过 PCI 术和药物治疗并不能持续有效改善患者的预后。PCI 术既不能逆转或减缓冠状动脉粥样硬化的生物学进程,也不能消除冠心病危险因素。多数患者存在的术后运动耐量下降及焦虑抑郁等精神问题,不仅严